Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.67 +3.7% SGZ 0.040 −11.1% GRSL 0.310 −3.1% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.67 +3.7% SGZ 0.040 −11.1% GRSL 0.310 −3.1%
Management

MediPharm Labs Announces CEO Transition: David Pidduck to Step Down; CFO Greg Hunter Appointed Interim CEO

By The Northwire Desk — AI Analysis Jan 19, 2026 · 08:00 LABS · 0.075 MEDIPHARM LABS CORP. J
LABS · Price

Executive Summary

  • David Pidduck will resign as Chief Executive Officer effective January 23, 2026; he will remain on the Board.
  • Greg Hunter, currently CFO, has been appointed Interim CEO while the Board evaluates a permanent successor.
  • The transition follows recent restructuring and integration of VIVO Cannabis Inc., with the Board expressing confidence in continued execution and growth under interim leadership.

Key Details

  • CEO Resignation: David Pidduck steps down as CEO effective 23 Jan 2026; will continue to serve on the Board of Directors.
  • Interim Appointment: Greg Hunter, CFO since Feb 2021, named Interim CEO and will retain his CFO responsibilities during the interim period.
  • Background – Outgoing CEO: Under Pidduck’s tenure, MediPharm completed restructuring initiatives, improved profitability, and integrated VIVO Cannabis Inc. (acquired April 2023).
  • Background – Incoming Interim CEO: Hunter has led cost‑reduction programs, strengthened financial/operational controls, and contributed to commercial strategy, pricing, customer programs, and supply chain alignment.
  • Board Statement: Chair Chris Taves thanked Pidduck for his contributions and expressed confidence in Hunter’s ability to drive execution, operational discipline, and focused growth during the transition.

Notable Quotes

“On behalf of the Board and the entire MediPharm Labs team, I want to thank David for his significant contributions… We are equally pleased to have a seasoned leader like Greg step into the Interim CEO role during this transition and the Board is confident in his ability to drive execution, operational discipline, and focused growth in the months ahead.” – Chris Taves, Chair of the Board.

Read the original news release →

More from MEDIPHARM LABS CORP. J

May 28, 2026 · 08:00

MediPharm Labs Turns EBITDA Positive Amidst Revenue Contraction and Governance Shifts

Regulatory May 13, 2026 · 07:30

MediPharm Labs scrapes to adjusted EBITDA profitability in Q1 2026, but a veteran affairs reimbursement cut looms large over its direct-to-patient business.

Earnings Apr 27, 2026 · 08:30

US Rescheduling Confirmed, But Canadian Revenue Headwinds Loom

Regulatory Mar 30, 2026 · 07:45

MediPharm Posts Margin Recovery and Steady International Growth, Yet Profitability Remains Elusive

Earnings Mar 25, 2026 · 19:05

MediPharm Delivers Margin Recovery and Near-Breakeven EBITDA as International Sales Offset Domestic Stagnation

Earnings Jan 13, 2026 · 18:47

Medipharm Labs signs Costa Rica supply agreement

M&A / Property